SB 216763抑制剂生物数据说明书M2061
gsk-3抑制剂sb216763对多囊卵巢综合征颗粒细胞gsk-3、irs-1表达的影响
Effect of GSK-3Inhibitor SB216763on Expression of Glycogen synthasekinese-3and Insulin Receptor Substrates-1of Granulosa cellsin PCOS.AbstractObjective:Polycystic ovarian syndrome(PCOS)is a common reproductive disorder, and its pathogenesis has Insulin resistance(IR).To investigate the effects of GSK-3 inhibitor SB216763on expression of Glycogen synthase kinese-3β(GSK-3β)and Insulin Receptor Substrates-1(IRS-1)in Granulosa cells of PCOS.Methods:Ovarian granulosa cells(GC)were collected from PCOS patients undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET)(n=20).Every sample of GC was inoculated in two culture bottles and cultured for3days.GSK-3inhibitor was added in one of them,and thus the two bottle of GC were divided into PCOS+IN group and PCOS group.Those ovarian GC from non-PCOS patients undergoing IVF/ICSI-ET used as control group(N-PCOS group)(n=16).The cultured ovarian GC of three groups were examined by Western Blotting for GSK-3,phosphorylated of p-GSK-3β(Ser9),and of p-IRS-1(Ser312).Result:The protein expression levels of GSK-3、p-GSK-3βin the GC of PCOS group were lower than N-PCOS group,while p-IRS-1were higher than N-PCOS group, statistically significant between the groups(P＜0.05).The protein expression levels of p-GSK-3βafter SB216763treatment(PCOS+IN)were lower than N-PCOS group,but were higher than PCOS group,mean while p-IRS-1were higher than N-PCOS group,but were lower than PCOS group,statistically significant between the groups(P＜0.05).The difference of protein expression level of GSK-3between PCOS and PCOS+IN group was not significant(P＞0.05).Conclusion:Activity of AKT/GSK-3signaling pathway in ovarian GC of PCOS is higher than non-PCOS.There is a link between IRS-1/MAPK signaling pathway and AKT/GSK-3signaling pathway,SB216763may decrease the activity of GSK-3and the expression of p-IRS-1.Postgraduate student:Yuan-yuan Wang（Obstetrics and Gynecology）Directed by Prof:Jian-xin LiuKey Words:Polycystic ovarian syndrome(PCOS);Granulosa cell(GC);Inhibitor; GSK-3；IRS-1目录引言 (1)材料和方法 (4)1研究对象 (4)2临床治疗方案 (4)3实验仪器与试剂 (5)3.1主要仪器 (5)3.2主要试剂及耗材 (6)4实验方法 (7)4.1主要溶液配置方法 (7)4.2黄素化颗粒细胞的提纯、原代培养及镜下观察 (9)4.3Western Blot检测各组GSK-3、p-GSK-3β（Ser9）、p-IRS-1（Ser312）表达量 (9)5统计学方法 (11)结果 (12)1患者一般资料 (12)2黄素化颗粒细胞的原代培养情况 (12)3Westen Blot检测各组颗粒细胞蛋白表达情况 (13)讨论 (14)1PCOS患者卵巢局部胰岛素作用途径缺陷 (15)2GSK-3抑制剂对PCOS卵巢局部IR作用 (16)3问题与展望 (17)结论 (18)参考文献 (19)综述 (22)综述参考文献 (31)附录 (36)攻读学位期间的研究成果 (38)致谢 (39)学位论文独创性声明、学位论文知识产权权属声明 (40)引言引言多囊卵巢综合征（Polycystic ovary syndrome，PCOS）作为一种妇科常见的生殖内分泌紊乱性疾患，临床患者主要表现为机体糖代谢异常及卵巢生殖功能障碍。
MK-2206 dihydrochloride_Akt123抑制剂_1032350-13-2_Apexbio产品说明书
1. Eren RO, Reverte M, et al. "Mammalian Innate Immune Response to a Leishmania-Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence." Cell Host Microbe. 2016 Sep 14;20(3):318-28. PMID:27593513 2. Winter PS, et al. "RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis." Sci Signal. 2014 Dec 23. PMID:25538080 3. Yoshida, S., et al. "Differential Signaling During Macropinocytosis in Response to M-CSF and PMA in Macrophages." Name: Frontiers in Physiology 6.8 (2015). 4. Fu, Xiu-Qiong, and Xue-Gang Sun. "Apigenin attenuates atherogenesis through inducing macrophage apoptosis via inhibition of AKT Ser473 phosphorylation and downregulation of plasminogen activator inhibitor-2." 5. Yoshida, Sei, et al. "Growth factor signaling to mTORC1 by amino acid–laden macropinosomes." The Journal of cell biology 211.1 (2015): 159-172. PMID:26438830 6. Zhang X, Lu X, Akhter S, Georgescu MM, "Legerski RJ. FANCI is a negative regulator of Akt activation. Cell Cycle. 2016 Apr 17;15(8):1134-43." PMID:27097374 7. Choy YY, Fraga M, et al. "The PI3K/Akt pathway is involved in procyanidin-mediated suppression of human colorectal cancer cell growth." Mol Carcinog. 2016 Jan 15. PMID:26774105
碧云天生物技术Oligomycin A产品说明书
碧云天生物技术/Beyotime Biotechnology订货热线：400-1683301或800-8283301订货e-mail：******************技术咨询：*****************网址：碧云天网站微信公众号Oligomycin A (ATPase抑制剂)产品编号产品名称包装SC0366-10mM Oligomycin A (ATPase抑制剂) 10mM×0.2mlSC0366-5mg Oligomycin A (ATPase抑制剂) 5mgSC0366-25mg Oligomycin A (ATPase抑制剂) 25mg产品简介：化学信息：化学名Spiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27, 2'-[2H]pyran]-3,9,13-trione,22-ethyl-3',4',5',6'-tetrahydro-7,11,14,15-tetrahydroxy-6'-[(2 R)-2-hydroxypropyl]-5',6,8,10,12,14,16,28,29-nonamethyl-, (1R,2'R,4E,5'S,6S,6'S,7R,8S,10R,11R,12S,14R,15S,16R,18 E,20E,22R,25S,28S,29R)-简称Oligomycin A别名oligomycin中文名寡霉素A化学式C45H74O11分子量791.06CAS号579-13-5纯度≥98%溶剂/溶解度Water <1mg/ml; DMSO 10mg/ml; Ethanol <1mg/ml溶液配制5mg加入0.63ml DMSO，或者每7.91mg加入1ml DMSO，配制成10mM溶液。
SC0366-10mM用DMSO配制。
ARG81662 Mouse MMP3 ELISA Kit说明书
Product datasheetARG81662Package: 96 wells Mouse MMP3 ELISA Kit Store at: 4°CComponentARG81662-001Antibody-coatedmicroplate 8 X 12 strips4°C. Unused stripsshould be sealedtightly in the air-tightpouch.ARG81662-002Standard 2 X 10 ng/vial4°CARG81662-003Standard/Samplediluent30 ml (Ready to use)4°CARG81662-004Antibody conjugateconcentrate (100X)1 vial (100 µl)4°CARG81662-005Antibody diluentbuffer12 ml (Ready to use)4°CARG81662-006HRP-Streptavidinconcentrate (100X)1 vial (100 µl)4°CARG81662-007HRP-Streptavidindiluent buffer12 ml (Ready to use)4°CARG81662-00825X Wash buffer20 ml4°CARG81662-009TMB substrate10 ml (Ready to use)4°C (Protect fromlight)ARG81662-010STOP solution10 ml (Ready to use)4°CARG81662-011Plate sealer 4 strips Room temperatureSummaryProduct Description ARG81662 Mouse MMP3 ELISA Kit is an Enzyme Immunoassay kit for the quantification of MouseMMP3 in serum, plasma (heparin) and cell culture supernatants.Tested Reactivity MsTested Application ELISASpecificity There is cross-reactivity with MMP10 approximately 2% and no detectable cross-reactivity with other MMPs.Target Name MMP3Conjugation HRPConjugation Note Substrate: TMB and read at 450 nm.Sensitivity78 pg/mlSample Type Serum, plasma (heparin) and cell culture supernatants.Standard Range156 - 10000 pg/mlSample Volume100 µlPrecision Intra-Assay CV: 5.4%; Inter-Assay CV: 6.6%Alternate Names Transin-1; CHDS6; EC 3.4.24.17; SL-1; STMY1; Matrix metalloproteinase-3; STR1; STMY; MMP-3;Stromelysin-1Application InstructionsAssay Time~ 5 hoursPropertiesForm96 wellStorage instruction Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose testreagents to heat, sun or strong light during storage and usage. Please refer to the product user manualfor detail temperatures of the components.Note For laboratory research only, not for drug, diagnostic or other use.BioinformationGene Symbol MMP3Gene Full Name matrix metallopeptidase 3Background Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellularmatrix in normal physiological processes, such as embryonic development, reproduction, and tissueremodeling, as well as in disease processes, such as arthritis and metastasis. Most MMP's are secretedas inactive proproteins which are activated when cleaved by extracellular proteinases. This geneencodes an enzyme which degrades fibronectin, laminin, collagens III, IV, IX, and X, and cartilageproteoglycans. The enzyme is thought to be involved in wound repair, progression of atherosclerosis,and tumor initiation. The gene is part of a cluster of MMP genes which localize to chromosome11q22.3. [provided by RefSeq, Jul 2008]Function Can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates procollagenase. [UniProt]Highlight Related products:MMP3 antibodies; MMP3 ELISA Kits;Related news:Detecting MMPs and their non-ECM substratesNew ELISA data calculation tool:Simplify the ELISA analysis by GainDataImagesARG81662 Mouse MMP3 ELISA Kit standard curve imageARG81662 Mouse MMP3 ELISA Kit results of a typical standard runwith optical density reading at 450 nm.。
硫酸拉罗替尼口服溶液说明书
核准日期：修改日期：硫酸拉罗替尼口服溶液说明书本品为附条件批准上市。
请仔细阅读说明书并在医师指导下使用【药品名称】通用名称：硫酸拉罗替尼口服溶液商品名：维泰凯® （VITRAKVI®）英文名称：Larotrectinib Sulfate Oral Solution汉语拼音：Liusuan Laluotini Koufu Rongye【成份】本品主要成份为硫酸拉罗替尼。
化学名称：（3S）-N-{5-[（2R）-2-（2,5-二氟苯基）-1-吡咯烷基]吡唑并[1,5-a]嘧啶-3-基}-3-羟基-1-吡咯烷甲酰胺硫酸盐。
化学结构式：分子式：C21H24F2N6O6S分子量：526.51辅料：羟丙基倍他环糊精、柠檬酸、柠檬酸钠、三氯蔗糖、苯甲酸钠、草莓味香料、纯化水。
【性状】本品为无色至黄色或橙色或红色或棕色液体。
【适应症】硫酸拉罗替尼口服溶液适用于符合下列条件的成人和儿童实体瘤患者，- 经充分验证的检测方法诊断为携带神经营养酪氨酸受体激酶（NTRK）融合基因且不包括已知获得性耐药突变。
- 患有局部晚期、转移性疾病或手术切除可能导致严重并发症的患者，以及-无满意替代治疗或既往治疗失败的患者。
本品为基于替代终点获得附条件批准上市，暂未获得临床终点数据，有效性和安全性尚待上市后进一步确证。
【规格】50ml：1.0g（按C21H22F2N6O2计）。
【用法用量】硫酸拉罗替尼口服溶液的治疗应由具有抗癌治疗经验的医生启动。
在使用本品治疗之前，必须确定患者肿瘤样本中携带NTRK融合基因。
应采用验证过的检测方法确定患者的NTRK融合基因状态。
经医院或实验室的检测结果判断为携带NTRK融合基因的患者能接受本品治疗，并且应经拜耳公司指定的独立第三方进行一次审核，证实患者确具有NTRK融合基因可继续用药。
剂量成人成人患者的推荐剂量为100 mg 拉罗替尼，每日两次，直至出现疾病进展或出现不可接受的毒性。
百泰 安全技术说明书
安全技术说明书页: 1/14 巴斯夫安全技术说明书按照GB/T 16483编制日期 / 本次修订: 10.01.2023版本: 11.2日期/上次修订: 17.12.2021上次版本: 11.1日期 / 首次编制: 29.11.2005产品: 百泰 Bai TaiProduct: Bai Tai(30359263/SDS_CPA_CN/ZH)印刷日期 29.10.20231. 化学品及企业标识百泰 Bai TaiBai Tai推荐用途和限制用途: 植物保护产品, 杀真菌剂公司:巴斯夫(中国)有限公司中国上海浦东江心沙路300号邮政编码 200137电话: +86 21 20391000传真号: +86 21 20394800E-mail地址: **********************紧急联络信息:巴斯夫紧急热线中心（中国）+86 21 5861-1199巴斯夫紧急热线中心（国际）:电话: +49 180 2273-112Company:BASF (China) Co., Ltd.300 Jiang Xin Sha RoadPu Dong Shanghai 200137, CHINA Telephone: +86 21 20391000Telefax number: +86 21 20394800E-mail address: ********************** Emergency information:Emergency Call Center (China):+86 21 5861-1199International emergency number: Telephone: +49 180 2273-1122. 危险性概述纯物质和混合物的分类:急性毒性: 分类5 (吸入-粉尘)急性毒性: 分类4 (口服)巴斯夫安全技术说明书日期 / 本次修订: 10.01.2023版本: 11.2产品: 百泰 Bai TaiProduct: Bai Tai(30359263/SDS_CPA_CN/ZH)印刷日期 29.10.2023皮肤腐蚀/刺激: 分类2特异性靶器官毒性-反复接触 (骨骼肌): 分类2对水环境的急性危害: 分类1对水环境的慢性危害: 分类1标签要素和警示性说明:图形符号警示词:警告危险性说明:H315造成皮肤刺激。